In this present report, we are describing a novel route for the synthesis of the tetracyclic ring systems, a common core of crinipellin, via oxidative dearomatization, cycloaddition and oxa- di-pi-methane rearrangement. We are also concerned to explore a route to tetracyclic core (1e) of Crinipellin and tricyclic core (1g) of Allicaol B through intermolecular diels alder reaction and photochemically 1,2 acyl shift. Moreover, docking study of compound 13 and 16 is investigated against AcrB multidrug efflux pump of Escherichia coli (PDB ID: 1T9U), main protease of SARS COV-2 (PDB ID: 6W63), DNA gyrase of Streptococcus pneumonia (PDB ID: 4Z2C), human estrogen receptor alpha (PDB ID: 3ERT), human lanosterol 14-alpha-demethylase (CYP51)(PDB ID: 3JUS) and cyclooxygenase-2 (Prostaglandin Synthase-2) (PDB ID: 1CX2). The obtained results are important for the exploitation of the therapeutic potential of these derivatives as antimicrobial, antiviral, anticancer, antifungal or anti-inflammatory agents. In addition, TD-DFT studies of the compounds are also carried out.

在本报告中，我们描述了通过氧化脱芳香化作用，环加成反应和氧-二-pi-甲烷重排合成四环环系统（crinipellin的共同核心）的新途径。我们还关注通过分子间狄尔斯al光反应和光化学上的1,2酰基转移，探索通向crinipellin的四环核心（1e）和Allicaol B的三环核心（1g）的途径。此外，还针对化合物的AcrB多药外排泵（大肠杆菌（PDB ID：1T9U），SARS COV-2的主要蛋白酶（PDB ID：6W63），链球菌肺炎的DNA促旋酶）对化合物13和16的对接研究进行了研究。（PDB ID：4Z2C），人雌激素受体α（PDB ID：3ERT），人羊毛甾醇14-α-脱甲基酶（CYP51）（PDB ID：3JUS）和环氧合酶2（前列腺素合酶2）（PDB ID：1CX2） 。获得的结果对于开发这些衍生物作为抗微生物剂，抗病毒剂，抗癌剂，抗真菌剂或抗炎剂的治疗潜力很重要。此外，还对化合物进行了TD-DFT研究。